GLP-1 & Incretin Science

Blocking the Brake on Muscle Growth

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Myostatin and related ligands restrain skeletal muscle growth by signalling through activin type II receptors. Blocking those receptors removes the restraint. Nunn and colleagues reported in Molecular Metabolism in 2024 that this preserves muscle mass and enhances fat loss during GLP-1 receptor agonism.

Key facts

Pathway
Myostatin / activin signalling
Target
Activin type II receptors
Normal role
Restrains muscle growth
Effect of blockade
Muscle preserved or increased
Additional reported effect
Enhanced fat loss
Mechanism paper
Nunn 2024 (PMID 38218536)

Why a brake on muscle growth exists

Muscle is metabolically expensive to build and maintain. An organism that built muscle without limit would waste energy it might need elsewhere, so growth is actively restrained. Myostatin is the principal restraining signal, and animals lacking functional myostatin are markedly more muscular, which is what established the pathway's role.

How the signal is delivered

Myostatin and related ligands bind activin type II receptors on muscle cells, initiating signalling that suppresses protein synthesis and promotes degradation. Blocking the receptor rather than the ligand catches several ligands converging on the same point, which is why the receptor is the more effective intervention target.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The finding that made this interesting for obesity

Nunn and colleagues titled their 2024 Molecular Metabolism paper to state it directly: antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. The second half is the surprise. The intervention did not merely protect muscle while fat loss continued unchanged; it reportedly increased fat loss.

Why enhanced fat loss is plausible rather than convenient

Muscle is metabolically active tissue. Preserving or increasing it maintains resting energy expenditure that would otherwise fall as mass is lost. A larger metabolically active compartment burning more energy is a coherent route from muscle preservation to greater fat loss, and it makes the combination more than the sum of two separate effects.

Why the combination logic is compelling

Incretin agonism reduces intake and produces loss across compartments. Activin receptor blockade shifts which compartment the loss comes from. The two act on different mechanisms with no obvious overlap, which is the profile that makes a combination worth testing rather than redundant.

What remains unestablished

Whether any of this translates to human functional outcomes, and what blocking a growth-restraining pathway does over years. Preclinical mechanism and Phase 2 body composition data are not the same as demonstrated clinical benefit, and no compound in this class holds an authorisation for obesity anywhere.

Frequently asked questions

What does myostatin do?

It restrains skeletal muscle growth by signalling through activin type II receptors, suppressing protein synthesis and promoting degradation.

Why block the receptor rather than myostatin itself?

Several ligands converge on the same receptor, so blocking it catches more of the signalling than blocking one ligand.

Does it only preserve muscle?

Nunn 2024 reports it also enhances fat loss during GLP-1 agonism, plausibly because preserved muscle maintains resting energy expenditure.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.